Equities Analysts Issue Forecasts for TARS FY2026 Earnings

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for Tarsus Pharmaceuticals in a research note issued on Wednesday, November 4th. HC Wainwright analyst M. Caufield now expects that the company will earn ($15.85) per share for the year, down from their previous estimate of ($2.25). HC Wainwright currently has a “Buy” rating and a $106.00 target price on the stock. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($2.23) per share. HC Wainwright also issued estimates for Tarsus Pharmaceuticals’ Q4 2026 earnings at ($0.55) EPS, FY2027 earnings at $1.37 EPS, FY2028 earnings at $3.65 EPS, FY2029 earnings at $5.97 EPS and FY2030 earnings at $8.49 EPS.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported ($14.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.46) by ($12.94). The company had revenue of $194.57 million for the quarter, compared to the consensus estimate of $187.83 million. Tarsus Pharmaceuticals had a negative net margin of 102.93% and a negative return on equity of 24.51%.

Other equities analysts have also recently issued research reports about the stock. Barclays initiated coverage on shares of Tarsus Pharmaceuticals in a research note on Wednesday, September 16th. They set an “overweight” rating and a $110.00 target price on the stock. The Goldman Sachs Group began coverage on shares of Tarsus Pharmaceuticals in a report on Thursday, September 24th. They issued a “buy” rating and a $116.00 price objective for the company. Zacks Research upgraded shares of Tarsus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 13th. Wall Street Zen cut Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Finally, Guggenheim boosted their target price on Tarsus Pharmaceuticals from $89.00 to $97.00 and gave the stock a “buy” rating in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Tarsus Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $104.57.

Tarsus Pharmaceuticals Stock Performance

TARS stock opened at $67.52 on Friday. The company has a 50-day simple moving average of $75.06 and a 200 day simple moving average of $67.83. The company has a market capitalization of $3.33 billion, a P/E ratio of -4.45 and a beta of 0.34. The company has a quick ratio of 3.17, a current ratio of 1.96 and a debt-to-equity ratio of 0.70. Tarsus Pharmaceuticals has a fifty-two week low of $53.89 and a fifty-two week high of $91.53.

Institutional Trading of Tarsus Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in Tarsus Pharmaceuticals during the second quarter worth approximately $242,705,000. Jupiter Topco LLC bought a new position in shares of Tarsus Pharmaceuticals in the second quarter valued at $176,834,000. Janus Henderson Group PLC increased its holdings in shares of Tarsus Pharmaceuticals by 16.1% in the first quarter. Janus Henderson Group PLC now owns 2,240,963 shares of the company’s stock valued at $157,223,000 after buying an additional 310,638 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of Tarsus Pharmaceuticals by 57.5% in the first quarter. Bank of America Corp DE now owns 1,194,377 shares of the company’s stock valued at $83,786,000 after buying an additional 436,271 shares in the last quarter. Finally, TimesSquare Capital Management LLC acquired a new stake in shares of Tarsus Pharmaceuticals during the 2nd quarter valued at $23,249,000. 90.01% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director William J. Phd Link sold 12,500 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $78.38, for a total transaction of $979,750.00. Following the completion of the transaction, the director owned 94,487 shares in the company, valued at approximately $7,405,891.06. This trade represents a 11.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Bobak R. Azamian sold 10,000 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $90.56, for a total transaction of $905,600.00. Following the completion of the transaction, the chief executive officer directly owned 827,991 shares in the company, valued at $74,982,864.96. This represents a 1.19% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 48,031 shares of company stock valued at $4,004,227 over the last three months. Company insiders own 9.64% of the company’s stock.

More Tarsus Pharmaceuticals News

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue rose 63.9% to about $194.5 million, with record sales of XDEMVY. Tarsus expects $715 million–$730 million in XDEMVY sales for 2026, supporting the growth outlook. Article: Tarsus expects $715M-$730M 2026 XDEMVY sales
• Positive Sentiment: Analysts raised price targets and maintained bullish ratings: Guggenheim lifted its target to $97 with a Buy rating, while Oppenheimer raised its target to $103 and kept an Outperform rating. Guggenheim rating Oppenheimer price target
• Neutral Sentiment: Management plans to participate in upcoming investor conferences; this may provide opportunities to discuss the business and outlook, but no new financial information was announced. Tarsus investor conference announcement
• Negative Sentiment: The quarterly net loss widened to $668 million, primarily due to acquisition-related costs, despite revenue growth. Tarsus also deferred European and Japanese filing plans, delaying potential international expansion. Q3 loss and XDEMVY sales Sales outlook and international filing plans

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a commercial-stage ophthalmic pharmaceutical company focused on developing and marketing treatments for eye diseases with significant unmet medical needs. The company’s portfolio is centered on therapies designed to address conditions affecting the ocular surface and eyelids.

Tarsus’ lead product is XDEMVY (lotilaner ophthalmic solution) 0.25%, an eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis, an inflammatory eyelid condition associated with an infestation of Demodex mites.